Bacterial endotoxin (LPS) elicits dramatic responses in the host including elevated plasma lipid levels due to the increased synthesis and secretion of triglyceride (TG)-rich lipoproteins by the liver, and the inhibition of lipoprotein lipase. This cytokine-induced hyperlipoproteinemia, clinically termed the `lipemia of sepsis', was customarily thought to represent the mobilization of lipid stores to fuel the host response to infection. However, since lipoproteins can also bind and neutralize LPS, we hypothesize that TG-rich lipoproteins (VLDL and chylomicrons) are also components of an innate, non-adaptive host immune response to infection. Herein we review data demonstrating the capacity of lipoproteins to bind LPS, protect against LPS-induced toxicity, and modulate the overall host response to this bacterial toxin. Lastly, we propose a pathway whereby lipoprotein-bound LPS may represent a novel, endogenous mechanism for regulating the hepatic acute phase response.
References
1.
Banerjee S., Bhaduri J.Serum protein-bound carbohydrates and lipids in cholera. Proc Soc Exp Biol Med1959; 101: 340—341.
2.
Gallin JI, Kaye D., O'Leary WM. Serum lipids in infection. N Engl J Med1969; 281: 1081—1086.
Wolfe RR, Shaw JH, Durkot MJEffect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am J Physiol1985; 248: E732—E740.
5.
Tripp RJ, Tabares A., Wang H., Lanza-Jacoby S.Altered hepatic production of apolipoproteins B and E in the fasted septic rat: factors in the development of hypertriglyceridemia. J Surg Res1993; 55: 465—472.
Feingold KR, Soued M., Staprans I. et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest1989; 83: 1116—1121.
8.
Feingold KR, Marshall M., Gulli R., Moser AH, Grunfeld C.Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb1994; 14: 1866—1872.
9.
Starnes Jr HF , Warren RS, Jeevanandam M. et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest1988; 82: 1321—1325.
10.
Nonogaki K. , Moser AH, Feingold KR, Grunfeld C.Alpha-adrenergic receptors mediate the hypertriglyceridemia induced by endotoxin, but not tumor necrosis factor, in rats. Endocrinology1994; 135: 2644—2650.
11.
Scholl RA, Lang CH, Bagby GJHypertriglyceridemia and its relation to tissue lipoprotein lipase activity in endotoxemic, Escherichia coli bacteremic, and polymicrobial septic rats . J Surg Res1984; 37: 394—401.
12.
Lanza-Jacoby S., Phetteplace H., Sedkova N., Knee G.Sequential alterations in tissue lipoprotein lipase, triglyceride secretion rates, and serum tumor necrosis factor alpha during Escherichia coli bacteremic sepsis in relation to the development of hypertriglyceridemia. Shock1998; 9: 46—51.
13.
Feingold KR , Staprans I., Memon RA et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res1992; 33: 1765—1776.
14.
Harris HW, Eichbaum EB, Kane JP, Rapp JHDetection of endotoxin in triglyceride-rich lipoproteins in vitro. J Lab Clin Med1991; 118: 186—193.
15.
Eichbaum EB , Harris HW, Kane JP, Rapp JHChylomicrons can inhibit endotoxin activity in vitro. J Surg Res1991; 51: 413—416.
16.
Ulevitch RJ , Johnston ARThe modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest1978; 62: 1313—1324.
17.
Ulevitch RJ , Johnston AR, Weinstein DBNew function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides . J Clin Invest1979; 64: 1516—1524.
18.
Ulevitch RJ , Johnston AR, Weinstein DBNew function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest1981; 67: 827—837.
19.
Van Lenten BJ , Fogelman AM, Haberland ME, Edwards PAThe role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA1986; 83: 2704—2708.
20.
Navab M., Hough GP, Van Lenten BJ, Berliner JA, Fogelman AMLow density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest1988; 81: 601—605.
21.
Harris HW, Grunfeld C., Feingold KR, Rapp JHHuman very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest1990; 86: 696—702.
22.
Wolff SMBiological effects of bacterial endotoxins in man. J Infect Dis1973; 128 (Suppl.): 259—264.
Cue JI, DiPiro JT, Brunner LJ et al. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits . Arch Surg1994; 129: 193—197.
25.
Rensen PC, Oosten M., Bilt E., Eck M., Kuiper J., Berkel TJHuman recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest1997; 99: 2438—2445.
26.
Rensen P., Van Oosten M., Van Amersfoort E., Van Eck M., Kuiper J., Van Berkel T.Apolipoprotein E is increased by bacterial LPS in vivo and protects against LPS-induced lethality. Circulation1998; 98 (Suppl.): I-305.
27.
de Bont N., Netea MG, Demacker PN et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res1999; 40: 680—685.
28.
Landmann R. , Muller B., Zimmerli W.CD14, new aspects of ligand and signal diversity . Microbes Infect2000; 2: 295—304.
Schutt C.Fighting infection: the role of lipopolysaccharide binding proteins CD14 and LBP. Pathobiology1999; 67: 227—229.
31.
Bernard A., Boumsell L.The clusters of differentiation (CD) defined by the First International Workshop on Human Leucocyte Differentiation Antigens. Hum Immunol1984; 11: 1—10.
32.
Van Voorhis WC, Steinman RM, Hair LS et al. Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages. J Exp Med1983; 158: 126—145.
33.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JCCD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein [see comments]. Science1990; 249: 1431—1433.
34.
Weinstein SL , June CH, DeFranco ALLipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. J Immunol1993; 151: 3829—3838.
35.
Haziot A., Chen S., Ferrero E., Low MG, Silber R., Goyert SMThe monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol1988; 141: 547—552.
36.
Maliszewski CR, Ball ED, Graziano RF, Fanger MWIsolation and characterization of My23, a myeloid cell-derived antigen reactive with the monoclonal antibody AML-2-23 . J Immunol1985; 135: 1929—1936.
37.
Bazil V., Horejsi V., Baudys M. et al. Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol1986 ; 16: 1583—1589.
38.
Pugin J., Schurer-Maly CC, Leturcq D., Moriarty A., Ulevitch RJ, Tobias PSLipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA1993; 90: 2744—2748.
39.
Frey EA, Miller DS, Jahr TG et al. Soluble CD14 participates in the response of cells to lipopolysaccharide . J Exp Med1992; 176: 1665—1671.
40.
Hailman E., Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med1994; 179: 269—277.
41.
Haziot A., Rong GW, Silver J., Goyert SMRecombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide . J Immunol1993; 151: 1500—1507.
42.
Read MA, Cordle SR, Veach RA, Carlisle CD, Hawiger J.Cell-free pool of CD14 mediates activation of transcription factor NFkappa B by lipopolysaccharide in human endothelial cells. Proc Natl Acad Sci USA1993; 90: 9887—9891.
43.
Ulevitch RJ , Tobias PSReceptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol1995 ; 13: 437—457.
44.
Beamer LJ, Carroll SF, Eisenberg D.Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. Science1997; 276: 1861—1864.
45.
Tall A.Plasma lipid transfer proteins. Annu Rev Biochem1995; 64: 235—257.
46.
Elsbach P.The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol1998; 64: 14—18.
47.
Bruce C., Beamer LJ, Tall ARThe implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein . Curr Opin Struct Biol1998; 8: 426—434.
48.
Yu B., Wright SDCatalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem1996; 271: 4100—4105.
49.
Wurfel MM, Wright SDLipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol1997; 158: 3925—3934.
50.
Vesy CJ, Kitchens RL, Wolfbauer G., Albers JJ, Munford RSLipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun2000; 68: 2410—2417.
51.
Kitchens RL , Wolfbauer G., Albers JJ, Munford RSPlasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem1999; 274: 34116—34122.
52.
Wurfel MM, Hailman E., Wright SDSoluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPSbinding protein and reconstituted high density lipoprotein. J Exp Med1995; 181: 1743—1754.
53.
Wurfel MM, Kunitake ST, Lichenstein H., Kane JP, Wright SDLipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med1994; 180: 1025—1035.
54.
Netea MG, Demacker PN, Kullberg BJ et al. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine1998; 10: 766—772.
55.
Medzhitov R. , Preston-Hurlburt P., Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [see comments]. Nature1997; 388: 394—397.
56.
Aderem A., Ulevitch RJToll-like receptors in the induction of the innate immune response. Nature2000; 406: 782—787.
57.
Brightbill HD, Modlin RLToll-like receptors: molecular mechanisms of the mammalian immune response. Immunology2000; 101: 1—10.
58.
Medzhitov R. , Janeway Jr C. Innate immunity. N Engl J Med2000; 343: 338—344.
59.
Read TE, Grunfeld C., Kumwenda Z. et al. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery1995; 117: 62—67.
60.
Read TE, Grunfeld C., Kumwenda ZL et al. Triglyceride-rich lipoproteins prevent septic death in rats . J Exp Med1995; 182: 267—272.
61.
Feingold KR , Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C.Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun1995 ; 63: 2041—2046.
Casas AT, Hubsch AP, Doran JEEffects of reconstituted high-density lipoprotein in persistent Gram-negative bacteremia. Am Surg1996; 62: 350—355.
66.
Pajkrt D., Doran JE, Koster F. et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med1996; 184: 1601—1608.
67.
Levine DM, Parker TS, Donnelly TM, Walsh A., Rubin ALIn vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA1993; 90: 12040—12044.
68.
Harris HW, Rockey DC, Young DM, Welch WJDiet-induced protection against lipopolysaccharide includes increased hepatic NO production. J Surg Res1999; 82: 339—345.
69.
van der Poll T., Braxton CC, Coyle SM et al. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun1995 ; 63: 3396—3400.
70.
van der Poll T., Coyle SM, Levi M. et al. Fat emulsion infusion potentiates coagulation activation during human endotoxemia. Thromb Haemost1996; 75: 83—86.
71.
Hajri T., Ferezou J., Lutton C.Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: phospholipids in excess are the main precursors of lipoprotein-X-like particles. Biochim Biophys Acta1990; 1047: 121—130.
72.
Ferezou J., Nguyen TL, Leray C. et al. Lipid composition and structure of commercial parenteral emulsions . Biochim Biophys Acta1994; 1213: 149—158.
73.
Hultin M., Carneheim C., Rosenqvist K., Olivecrona T.Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons . J Lipid Res1995; 36: 2174—2184.
74.
Abe M., Kawano M., Tashiro T. et al. Catabolism of lipoprotein-X induced by infusion of 10% fat emulsion . Nutrition1997; 13: 417—421.
75.
Karpe F., Hultin M.Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway . J Lipid Res1995; 36: 1557—1566.
76.
Tashiro T., Mashima Y., Yamamori H., Sanada M., Nishizawa M., Okui K.Intravenous intralipid 10% vs. 20%, hyperlipidemia, and increase in lipoprotein X in humans. Nutrition1992; 8: 155—160.
77.
Harris HW, Grunfeld C., Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest1993; 91: 1028—1034.
78.
Harris HW, Rockey DC, Chau P.Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats. Hepatology1998; 27: 1341—1348.
79.
Harris H.Fasting and postprandial lipoproteins abrogate the effects of endotoxin in humans. In: Faist E. (ed) 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Bologna: Monduzzi, 1996; 41—44.
80.
Flegel WA, Wolpl A., Mannel DN, Northoff H.Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins . Infect Immun1989; 57: 2237—2245.
81.
Weinstock C. , Ullrich H., Hohe R. et al. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler Thromb1992; 12: 341—347.
82.
Flegel WA, Baumstark MW, Weinstock C., Berg A., Northoff H.Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun1993; 61: 5140—5146.
83.
Read TE, Harris HW, Grunfeld C., Feingold KR, Kane JP, Rapp JHThe protective effect of serum lipoproteins against bacterial lipopolysaccharide . Eur Heart J1993; 14 (Suppl. K): 125—129.
84.
Kumwenda Z. , Welch W., Harris H.Chylomicron-bound endotoxin inhibits hepatocellular nitric oxide production by inhibiting nuclear factor κB activation in rats. Surg Forum1998; 49: 8—9.
